Alnylam Presents Phase I Data at ASCO Showing Liver Cancer Drug Well Tolerated
June 09, 2011
Alnylam Presents Phase I Data at ASCO Showing Liver Cancer Drug Well Tolerated
Alnylam partner Tekmira Pharmaceuticals said it views the data as a validation of its drug-delivery technology, which will be used in two new oncology programs it unveiled this week.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Tekmira Provides Pipeline Update, Eyes Agricultural Market
February 14, 2013 / Gene Silencing News - Tekmira Says Pipeline on Track Heading into Q4; Holds Course on Alnylam Litigation
November 10, 2011 / Gene Silencing News - ASCO Publishes Abstracts for Alnylam, Silence Cancer Drugs
May 26, 2011 / Gene Silencing News - Tekmira Releases Phase I Cancer Drug Data, Plans Phase II Trial in Neuroendocrine Tumors
April 11, 2013 / Gene Silencing News - Tekmira to Present Cancer Drug Data at AACR, Aims for Phase II by Year-End
March 28, 2013 / Gene Silencing News